Review on nasal drug delivery system with recent advancemnt

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 3, Issue SUPPL. 2, 2011, Pages 6-11

  Rahisuddin, ^a   Sharma, Pramod K ^a   Garg, Garima ^a   Salim, Mohd ^a  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

Drug delivery; Gastric degradation; Hepatic first pass metabolism; Nasal route

Indexed keywords

EXCIPIENT; VACCINE;

BLOOD FLOW; DIGESTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; ENZYMATIC DEGRADATION; FIRST PASS EFFECT; HUMAN; LIPOPHILICITY; MOLECULAR WEIGHT; MUCOCILIARY CLEARANCE; NASAL DRUG DELIVERY SYSTEM; NOSE CAVITY; PH; PHYSICAL CHEMISTRY; PKA; REVIEW; VISCOSITY;

EID: 79959458273     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Chein YW, KSE. Su and S.F. Chang. Nasal systemic drug delivery. Dekker, 1989; 1-77
2. Beht et al. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv.Drug.Del.Rev, 1998; 29: 117-133.
3. Sharma PK, Chaudhari P, Kolsure P, Ajab A, Varia N. Recent trends in nasal drug delivery system -an overview. 2006; 5: vol 4.
4. Romeo VD, Meireles J, Sileno AP, Pimplaskar HK, Behl CR. Effects of physicochemical properties and other factors on systemic nasal delivery. Adv Drug Deliv Rev, 1998; 29: 89-116.
5. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today, 2002; 7:1184-1189.
6. Graff LC, Pollock GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci, 2005; 94: 1187-1195.
7. Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm, 2007; 335: 138-146.
8. Alagusundram M, chengaiah B, gnanaprakash K, ramakanth S, chetty CM, dhachinamoorthi D.nasal drug delivery system-an overview. Int. J. Res. Pharm. Sci. Vol-1, Issue-4, 454-465, 2010
9. M E Aulton Pharmaceutics: The science of dosage form design. Churchill Livingston, 2002; 494-503.
10. Krishnamurthy R, Mitra AK. Prodrug for nasal drug delivery, Acta. Drug Del. Rev, 1998; 29: 135-146.
11. Kadam S.S., Mahadik, K.R., Pawar, A.P, Paradkar, A.R., Transnasal delivery of peptides - a review, The East. Pharm. July 1993; 47-49.
12. Hirai S, Yashiki T, Mima H. Effect of surfactants on nasal absorption of insulin in rats, Int. J. Pharm, 1981; 9: 165-171.
13. Illum L. Mathiowitz E, Chickering DE, Lehr CM Ed, Bioadhesive formulations for nasal peptide delivery: Fundamentals, Novel Approaches and Development. Marcel Dekker. New York, 1999; 507-539.
14. Aurora J. Development of Nasal Delivery Systems. A Review. Drug Deliv Technol 2002; 2(7): 1-8.
15. Dodane V, Khan MA, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999; 182: 21-32.
16. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the systemic and CNS specific delivery administration of its water soluble prodrugs of L-dopa by the nasal. Pharm Res, 2000; 17: 978-984.
17. Merkus FW, Verhoef JCNG, Marttin E. Nasal Mucociliary clearance, as a factor in nasal drug delivery. Adv Drug Deliv Rev, 1998; 29:13-38.
18. Schipper N, Verhoef J, Merkus FW. The nasal Mucociliary clearance: Relevance to nasal drug delivery. Pharm Res, 1991; 8: 807-814.
19. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of Mucociliary clearance in health and disease. Eur Respir J, 1999; 13:1177-1188.
20. Afzelius B.A, The lung: Scientific Foundations, Lippincott- Raven, Philadelphia, 1997.
21. Bogdanffy MS. Biotransformation enzymes in the rodent nasal mucosa: The value of a histochemical approach. Environ Health Perspective, 1990; 85: 177-186.
22. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res, 1992; 9: 1-9.
23. Lee VH, Yamamoto A. Penetration and enzymatic barriers of peptide and protein absorption. Adv Drug Deliv Rev, 1990; 4: 171-207.
24. Pires A, Fortuna A, Alves G, and Falcão A. Intranasal Drug Delivery: How, Why and What for? J Pharm Pharmaceut Sci (www.cspsCanada.org) 12(3) 288-311, 2009.
25. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm, 2007; 337: 1-24.
26. Graff CL, Pollack GM. Functional Evidence for P-glycoprotein at the Nose-Brain Barrier. Pharm Res, 2005; 22: 86-93.
27. Graff CL, Pollack GM. P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res, 2003; 20: 1225-1230.
28. McMartin C. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci, 1987; 76: 535-540.
29. Corbo DC. Characterization of the barrier properties of mucosal membranes. J Pharm Sci, 1990; 79: 202-206.
30. Fisher A, Illum L, Davis S, Schacht E. Diiodo-L-tyrosine labelled dextrans as molecular size markers of nasal absorption in the rat. J Pharm Pharmacol, 1992; 44: 550-554.
31. Corbo DC. Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm Res, 1989; 6: 848-852.
32. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf, 2000; 23: 11-33.
33. Washington N, Steele RJ, Jackson SJ, Bush D, Mason J, Gill DA, Pitt K, Rawlins DA. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm, 2000; 198: 139-146.
34. Hirai S, Yashiki T, Matsuzawa T, Mima H. Absorption of drugs from the nasal mucosa of rats. Int J Pharm, 1981; 7: 317-325.
35. Zaki NM, Awad GA, Mortada ND, Abd El Hady SS. Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats. Int J Pharm, 2006; 327: 89-96.
36. Dahl AR, Lewis JL. Respiratory tract uptake of inhalants and metabolism of xenobiotics. Annu Rev Pharmacol Toxicol, 1993; 33: 383-407.
37. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today, 2002; 7: 967-975.
38. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm, 2007; 337: 1-24.
39. Huang CH, Kimura R, Nassar RB, Hussain A. Mechanism of nasal absorption of drugs. I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci, 1985; 74: 608-611.
40. Bernkop-Schnurch A. Use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release, 1998; 52: 1-16.
41. Heidari A, Sadrai H, Varshosaz J. Nasal delivery of insulin using bioadhesive chitosan gels. Drug Deliv, 2006; 13: 31-38.
42. Alsarra IA, Hamed AY, Mahrous GM, El Maghraby GM, Al-Robayan AA, Alanazi FK. Mucoadhesive polymeric hydrogels for nasal delivery of Acyclovir. Drug Dev Ind Pharm, 2009; 35: 352-362.
43. Kilian N, Müller DG. The effect of a viscosity and an absorption enhancer on the intra nasal absorption of metoprolol in rats. Int J Pharm, 1998; 163: 211-217.
44. Afzelius B.A, The lung: Scientific Foundations, Lippincott- Raven, Philadelphia, 1997.
45. Stoke DG, Reber KR, Waltzman LS, Erns C, Hamilton D, Gawareck D, Mermelstein F, McNicol E, Wright C, Carr DB. Analgesic efficacy and safety of morphine-chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med, 2008; 9: 3-12.
46. Kilian N, Müller DG. The effect of a viscosity and an absorption enhancer on the intra nasal absorption of metoprolol in rats. Int J Pharm, 1998; 163: 211-217.
47. Patil SB, Sawant KK. Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J Microencapsul, 2008; 9: 1-12.
48. Ding WX, Qi XR, Fu Q, Piao HS. Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. Drug Deliv, 2007; 14: 101-104.
49. Rathnam G, Narayanan N, Ilavarasan R. Carbopol-based gels for nasal delivery of progesterone. AAPS Pharm Sci Tech, 2008; 9: 1078-1082.
50. Yu S, Zhao Y, Wu F, Zhang X, Lü W, Zhang H, Zhang Q. Nasal insulin delivery in the chitosan solution: in vitro and in vivo studies. Int J Pharm, 2004; 281: 11-23.
51. Onischuk AA, Tolstikova TG, Sorokina IV. Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv, 2008; 21: 231-243.
52. Leykin Y, Casati A, Rapotec A. A prospective, randomized, double-blind comparison between parecoxib and ketorolac for early postoperative analgesia following nasal surgery. Minerva Anestesiol, 2008; 74: 475-479.
53. Moodie JE, Brown CR, Bisley EJ. The safety and analgesic efficacy of intranasal ketorolac in patients with postoperative pain. Anesth Analg, 2008; 107: 2025-2031.
54. Shao Z, Park GB, Krishnamoorthy R, Mitra AK. The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2'-ester prodrugs. Pharm Res, 1994; 11: 237-242.
55. Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine, 2004; 23: 794-801.
56. Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine, 2006; 24: 1601-1608.9.
57. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC.Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine, 2005; 23: 1029-1036.
58. Drabick JJ, Brandt BL, Moran EE, Saunders NB, Shoemaker DR, Zollinger WD. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers.Vaccine, 2000; 18:160-172.
59. Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus in infants and young children. J Infect Dis, 2004; 190: 2096-2103.
60. Greenberg DP, Walker RE, Min-Shi L, Reisinger KS. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis, 2005; 191: 1116-1122.
61. Anaísa Pires, Ana Fortuna, Gilberto Alves and Amílcar Falcao. Intranasal Drug Delivery: How, Why and What for? J Pharm Pharmaceut Sci (www.cspsCanada.org) 2009; 12(3): 288-311.